Pharmaceutical company GlaxoSmithKline is to pay $3 billion (£1.9bn) to settle several US federal investigations into some of its best selling drugs. On 2 July, the company confirmed a provisional settlement reached in November last year after an eight-year investigation. GSK has admitted to marketing antidepressants Paxil and Wellbutrin for unapproved uses. Also, the firm has conceded charges that it held back data about the diabetes drug Avandia.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.